|
| Author | Years of enrollment | | Approach (T, V, R) | Resection(s) included
(W, S, L, B, P) | Age | Clinical stages included | Pathologic stage | Complication rate (% overall), severe | Predictors of increased complications ( values) | 30-day perioperative mortaiity (%) | 5-year survival
| Predictors of poor survival ( value) |
|
| Port et al. [9] | 1998–2009 | 121 | V = 40
T = 81 | L | ≥80
(median 82) | — | I 65.3%
II 25.0%
III 10.0% | 53.7%, 28.9% severe requiring significant intervention | Thoracotomy (63%) versus VATS (35%) = 0.004 | 1.7% | 56.6%
By stage:
I = 69.6%
II = 35.6%
III = 18.2% | Pathologic stage Ib or greater ( = 0.050) |
|
Hanagiri et al. [18]
| 1992–1995 | 18 | T | S, L, W | ≥80 (mean, 82.1) | IA 6
IB 6
IIB 1
IIIA 5 | IA 4
IB 5
IIB 4
IIIA 1
IIIB 4 | 50% | — | 0% | — | — |
|
| Aoki et al. [7] | 1981–1998 | 35 | — | W or S 10
L 25
| ≥80
(mean 81.2) | IA 14
IB 10
IIA 0
IIB 5
IIIA 5
IIIB 1 | — | 60% | — | 0% | 39.8% | — |
|
| Pagni et al. [8] | 1980–1995 | 54 | T | W 3
S 3
L 43
B 2
P 1
chest wall 1
sleeve 1
| ≥80
| I
II
IIIA | — | 42%, 11% | — | 3.7% | 43% | >stage I ( value not given) |
|
| Clavien et al. [19] | 2000–2009 | 191 | V 77%
T
| W 77
S 13
L 96
P 3 | ≥80
(median 82) | — | I 56%
II 10%
III 9%
IV 3% | 46% | Resection greater than wedge
( = 0.0064), thoracotomy as approach ( = 0.034), % predicted FEV1 for ea 10% decrement ( = 0.01) | 3.6% | 3-year stage I (109 patients) 56% | — |
|
Umezu et al. [10]
| 2001–2008 | 44 | | | ≥80 (mean 82) | | | 65.9% | | 2.3% | 54.5% | |
|
Okada et al. [17]
| | 44 | | | ≥80 (mean 81.8) | | | 20% | | 0 | 44.9% | |
|
| Okami et al. [11] | 1999 | 367 | — | W 80
S 42
L 245
| 80–90 (mean 82) | I | I 300
II 44
III 23 | 8.4% | Comorbidity and mediastinal lymph node dissection | 1.4% | 56.1% | Advanced pathologic stage and comorbidity |
|
| Chida et al. [16] | 1981–2006 | 48 | — | S 3
L 45
P 2 | ≥80 (mean 81.7) | I 36
II 3
III 9 | I 30
II 8
III 10 | 68.8% | Mediastinal LN dissection ( = 0.004) | — | 35% | Med LN dissection ( = 0.022) |
|
| Suemitsu et al. [15] | 1981–2006 | 146 | — | W 38 (26%)
S 17 (11.6%)
L 79 (54.1%)
B 7 (4.8%)
P 1 (0.7%)
Explorations 4 (2.7%) | ≥80 (mean 82.6) | I 109 (74.7%)
II 14 (9.6%)
III 22 (15.1%)
IV 1 (0.7%) | I 94 (64.3%)
II 16 (11.0%)
III 31 (21.2%)
IV 5 (3.5%) | — | — | — | 46.8% | — |
|
| Mun and Kohno [14] | 1999–2006 | 55 | V | W 10 (18.2%)
S 7 (12.7%)
L 37 (67.3%)
B 1 (1.8%)
| 80–89 (mean 82.7) | IA 32
IB 23 | I 44
II 6
III 5 | 25.6% | — | 3.6% | 65.9% | — |
|
| Ikeda et al. [13] | 1981–2002 | 73 | V and T | L 45 (62%)
B 2 (2.7%)
S 6 (8.2%)
W 20 (27%) | 80–89 (mean 83) | I 60
II 10
IIIA 3 | I 55 (74.3%)
II 8 (11%)
IIIA 5 (6.8%)
IIIB 4 (5.5%)
IV 1 (1.4%) | 37% | — | 4.1% | 47% | Pathologic stage III compared to II ( = 0.02) |
|
| Matsuoka et al. [12] | 1997–2004 | 40 | 85% Muscle sparing PLT/VATS, 15%
standard PLT | W 30%
S 30%
L 40%
| 80–89 | — | IA 52.5%
iB 35.5%
IIA 0
IIB 7.5%
IIIA 5% | 20% | — | 0% | 56.9% | — |
|
| Current Study | 2004–2012 | 45 | T 59%
V 26%
R 26% | L | ≥80 (mean 82)
| IA 51%
IB 21%
IIA 11%
IIB 2.2%
IIIA 11%
| IA 26%
IB 33%
IIA 8%
IIB 8%
IIIA 18%
IIIB 3%
IV 5% | 62%, 17% | — | 2% | 52% | — |
|
